Zimmer Biomet Insiders Sold Before $1.90 EPS Beat
Two senior Zimmer Biomet executives sold a combined $824,028 in shares in September, six weeks before the company announced Q3 earnings of $1.90 per share, beating consensus by 1.1%. The timing raises
ZBH Executives Sold Before Fourth-Straight Earnings Beat
NEW YORK, November 15 —
Before Zimmer Biomet Holdings, Inc. (ZBH) disclosed a fourth consecutive EPS beat on November 4, 2026, two of its most operationally senior officers had sold a combined $824,028 in shares at prices the market has since left behind. Whether that reflects routine diversification or operational awareness the headline numbers do not capture is what the filings raise.
- Most recent quarterly EPS: $1.90 actual vs. $1.88 estimated, the smallest beat in a four-quarter positive streak
- September insider sales: Thornal sold 5,691 shares at $92.95; Phipps sold 3,000 at $98.35; zero purchases in the window
- Net debt of $7.23 billion against trailing free cash flow of $1.44 billion; shares trade at $103.21
The Selling Window
Kevin R. Thornal, ZBH's Group President of Global Business, sold 5,691 shares in an open-market transaction on September 11, six weeks before Q3 results were public. Chad F. Phipps, another senior officer, sold 3,000 shares the week prior. Both transactions priced 5-10% below current levels, and no insider purchased shares across the 90-day window. Zimmer Biomet manufactures knee and hip replacement systems for orthopedic surgeons and hospitals worldwide, and also deploys the ROSA Robot for implant-positioning and the ZBEdge platform for surgical data analytics. The executives with the most direct operational visibility to that business chose to cut exposure ahead of a quarter the market rewarded.
A Streak in Compression
ZBH's Q3 EPS of $1.90, reported via 8-K on November 4, cleared the $1.88 consensus by 1.1%, the narrowest positive surprise in a four-quarter streak that peaked at 12.3% two periods prior. That compression in the size of outperformance, even as the streak itself remains intact, is the financial subplot running beneath the insider timing question. Revenue of $8.57 billion is growing at 3.1% annually, leaving little room for execution errors, and gross margin of 69.3% leaves the company dependent on volume rather than cost discipline for further earnings growth. A thinning beat streak at steady margin is a different setup than an expanding one.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ZBH | $19.5B | 11.5x | +16.4% |
| IQV | $43.7B | 18.7x | +22.7% |
| TFX | $6.2B | 14.2x | +49.3% |
| COO | $11.9B | 13.4x | -12.2% |
| EW | $61.6B | 31.6x | +26.4% |
| FTV | $20.2B | 20.4x | +34.4% |
Debt Builds, Beats Narrow
On November 12, ZBH filed an 8-K reporting entry into a material definitive agreement and a new direct financial obligation, following four 424B5 prospectus supplements tied to debt capital markets activity in early November. Against $7.23 billion in net debt, the cost and structure of any new obligation directly frames the debt picture. A consensus price target of $116.19, roughly 12.6% above where the stock trades, shows analyst confidence in continued execution. The checkpoint to watch next quarter: whether four becomes five, and at what margin. Run the free Zimmer Biomet Holdings, Inc. deep-dive, or test the valuation assumptions with the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Zimmer Biomet executives sell before Q3 earnings?
Yes. Two senior executives, Kevin Thornal (Group President of Global Business) and Chad Phipps, sold a combined $824,028 in shares in September. Thornal sold 5,691 shares at $92.95 on September 11, and Phipps sold 3,000 shares at $98.35 the week prior, both at prices 5-10% below the current level of $103.21. No insiders purchased shares during the 90-day window.
What were ZBH's Q3 earnings results?
ZBH reported Q3 EPS of $1.90, beating the consensus estimate of $1.88 by 1.1%. This marked the fourth consecutive quarter of an EPS beat, though the margin has narrowed from a peak of 12.3% two quarters earlier. Revenue reached $8.57 billion with 3.1% annual growth and gross margin of 69.3%.
Why does the narrowing beat streak matter?
The compression in the magnitude of outperformance suggests diminishing room for execution error. With revenue growing at only 3.1% annually and margins steady, the company is more dependent on volume for future earnings growth. The article notes this "thinning beat streak at steady margin is a different setup than an expanding one."
What is ZBH's leverage position?
ZBH carries $7.23 billion in net debt against trailing free cash flow of $1.44 billion. On November 12, the company filed an 8-K reporting entry into a material definitive agreement and new direct financial obligations following debt capital markets activity in early November.
What is the consensus outlook on ZBH stock?
Analysts have set a consensus price target of $116.19, roughly 12.6% above the current trading level, reflecting confidence in continued execution despite the narrowing beat margin.
Zimmer Biomet disclosed its fourth consecutive EPS beat on November 4, 2026, yet two of its most senior executives had already sold a combined $824,000 in shares during the two months prior at prices below where the stock now trades. The question the evidence raises: whether executives closest to global operations saw something the headline number does not.